MEK inhibitors initially emerged as potential anti-cancer agents in the mid-1990s, with several MEK1 and MEK1/2 inhibitors entering clinical trials for RAS-driven cancers in the early 2010s [88,89]. Here, MAP2K1 is linked to cancer.